title: [Systemic therapy for advanced endometrial cancer].
abstract: Endometrial cancer has generally a good prognosis when it is diagnosed at an early stage but remains incurable at an advanced stage (recurrent or metastatic) with only few therapeutic options. Hormone therapy is the treatment of choice in case of slowly progressive disease with a tumor expressing hormonal receptors due to its favorable safety profile. Taxanes, anthracyclines and platinum compounds are the most active chemotherapy agents with greater response rates when they are combined at the price of a significant toxicity. Targeted therapies based on a better understanding of tumor biology are being evaluated with some promising results.
authors.affiliation: Institut Gustave-Roussy, département de médecine, comité de gynécologie, Villejuif, France. youssef.tazi@igr.fr
authors.forename: Youssef
authors.initials: Y
authors.lastname: Tazi
authors.forename: Patricia
authors.initials: P
authors.lastname: Pautier
authors.forename: Catherine
authors.initials: C
authors.lastname: Lhommé
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D066246:ErbB Receptors; D058570:TOR Serine-Threonine Kinases